This page tracks congressional stock trading activity in Fulgent Genetics, Inc. (FLGT) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving FLGT. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of February 2026 — Disclosed Capitol has tracked 4 disclosed congressional trades in Fulgent Genetics, Inc. (FLGT) — 4 buys with no recorded sells — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Feb 6, 2026 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Nov 27, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Nov 17, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| Jan 14, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in Fulgent Genetics, Inc. (FLGT), members of Congress have reported 4 buys and 0 sells. The average 30-day alpha vs. the S&P 500 is -14.71%.
As of August 2026, corporate insiders at Fulgent Genetics, Inc. have filed 7 SEC Form 4 transactions in FLGT over the past 12 months — including 2 sells worth $42K.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-08-27 | Xie Jian — President and COO | Sale | $24K |
| 2026-08-27 | Gao Hanlin — Chief Scientific Officer | Sale | $19K |
| 2026-08-26 | Hsieh Ming — Chief Executive Officer | Tax Withholding | $58K |
| 2026-08-26 | Kim Paul — CFO and Treasurer | Tax Withholding | $23K |
| 2026-07-26 | Kim Paul — CFO and Treasurer | Tax Withholding | $54K |
| 2026-07-26 | Xie Jian — President and COO | Tax Withholding | $86K |
| 2026-07-26 | Gao Hanlin — Chief Scientific Officer | Tax Withholding | $32K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Fulgent Genetics, Inc. reported revenue of $322.7M and net income of -$60.5M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $85.4M, net income -$29.5M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.